Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gie.2014.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Nat Med
January 2025
Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, CO, USA.
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.
View Article and Find Full Text PDFThe clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review.
Orphanet J Rare Dis
December 2024
Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.
Background: Bile acid synthesis defects (BASDs) can be severely disabling involving the liver and nervous system, potentially due to elevated levels of toxic C-bile acid intermediates. Cholic acid (CA) supplementation is hypothesized to decrease bile acid production, stimulate bile secretion and -flow, and slowing down disease progression. This systematic review assesses the clinical and biochemical effectiveness, and safety of CA in BASDs patients.
View Article and Find Full Text PDFFirst-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Front Oncol
October 2024
New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States.
Article Synopsis
- Transforming growth factor (TGF)-ß1 is known to encourage tumor growth while also suppressing the immune system's ability to fight tumors; its latent form is associated with glycoprotein-A repetition predominant (GARP) on regulatory T cells.
- Livmoniplimab is a monoclonal antibody that targets the GARP:TGF-ß1 complex to impede the activation and release of TGF-ß1, and it's being studied in combination with another antibody, budigalimab, in a clinical trial for patients with advanced solid tumors.
- In the trial, 57 patients were treated with dosages ranging up to 1500mg, with manageable side effects like fatigue and nausea reported; while no
Characteristics of Rhizospheric Fungal Community along Huangshan Mountain's Elevation Gradients, China.
J Fungi (Basel)
September 2024
School of Resources and Environmental Engineering, Anhui University, Hefei 230601, China.
Elevation gradients strongly influence the diversity pattern of soil microorganisms. To date, many studies have elucidated the response of soil microbes to changes in elevation gradients. However, the effects of these gradients on the assembly mechanisms and network complexity of rhizospheric microbial communities remain underexplored.
View Article and Find Full Text PDFPhysician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast.
Target Oncol
November 2024
The Royal Marsden NHS Foundation Trust, London, UK.
Article Synopsis
- Cisplatin-based adjuvant chemoradiotherapy (CRT) is the standard for high-risk locally advanced squamous cell carcinoma of the head and neck but isn't suitable for all patients due to factors like age and kidney function.
- Many patients who can't receive cisplatin have poor outcomes with just radiotherapy, indicating a significant need for alternative treatments.
- The podcast explores cisplatin ineligibility, the lack of clear treatment options for affected patients, and discusses ongoing clinical trials that might introduce new therapies.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!